Abeona Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-28.1%projected annual EPS growth
Analyst Coverage
7analysts covering
FY EPS (est.)
-$0.68next fiscal year
Monitoring Framework
Key Performance Indicators
ZEVASKYN Commercial Patient Treatments Quarterly3.0Target: Steady cadence of treatments and scaling up in 2026
Qualified Treatment Centers (QTCs) Activated Quarterly6.0Target: Continued expansion of the QTC network
Net Product Revenue Quarterly8.7MTarget: 27500000 by Q2 2027
Watch Items
- Commercial launch execution and scaling of ZEVASKYNTrigger: Slower than expected biopsy-to-treatment conversion ratesAction: Optimize hospital logistics, patient identification, and Qualified Treatment Center onboarding
- Operating expenses and cash burn rateTrigger: Quarterly cash burn exceeding $23 million without corresponding revenue growthAction: Implement cost-containment measures and optimize commercial SG&A spend
- Payer coverage and reimbursement policiesTrigger: Decline in the percentage of commercially insured lives covered below 95%Action: Engage in outcomes-based pricing negotiations and expand Medicaid/commercial payer mix
Research as of 20 Jun 2026